FTSE 100 news / Companies and sectors / AstraZeneca / 7 October 2026
AstraZeneca (AZN): news on Wednesday 7 October 2026
+7.8 strongly positive
Coverage was dominated by the opening of AstraZeneca's $1bn R&D hub in Massachusetts, alongside Citi's higher price target on strong clinical data and the completed $2bn Summit investment. Analyst Buy ratings and a share price gain added to the positive lean, with only a drug-pricing legal challenge on the negative side.
What drove it
- Massachusetts R&D hub
- Citi target upgrade
- Summit investment
The 36 stories
- +10.0 Citi raises AstraZeneca target to £186 as tozorakimab prospects improve
Citi target raised as tozorakimab prospects improve - +10.0 Citi raises AstraZeneca target price to £186 on improved drug prospects and strong clinical data
Citi raises target to £186 on strong data - +10.0 Citigroup raises AstraZeneca price target after strong clinical trial results
Citigroup raises target on strong trial results - +9.2 AstraZeneca opens $1B-plus R&D hub in Massachusetts
Major $1bn-plus R&D hub opened - +8.3 AstraZeneca Opens Strategic R&D Center in Massachusetts
Strategic R&D centre opened - +8.3 AstraZeneca opens new global strategic R&D center in USA
New global strategic R&D centre in US - +8.3 AstraZeneca Opens New Global Strategic R&D Centre in Cambridge
New global R&D centre opened - +8.3 AstraZeneca Plans $1-Billion Spend to Grow Massachusetts Presence
$1bn spend to expand US presence - +8.3 AstraZeneca opens $1bn R&D centre in US
$1bn US R&D centre opened - +8.3 AstraZeneca launches new $1 billion global R&D hub in Kendall Square, Cambridge, Massachusetts
Launches $1bn R&D hub in Cambridge - +7.5 AstraZeneca cuts ribbon on new R&D facility in Massachusetts
New Massachusetts R&D facility opened - +7.5 AstraZeneca PLC : Jefferies gives a Buy rating
Jefferies Buy rating supportive - +7.5 AstraZeneca heralds new R&D facility in that ‘other’ Cambridge
New R&D facility announced - +7.5 AstraZeneca PLC : Bernstein reaffirms its Buy rating
Bernstein reaffirms Buy rating - +7.5 What to know about AstraZeneca’s tremendous new R&D center in Kendall Square
Coverage of new Kendall Square R&D centre - +7.5 AstraZeneca Opens New Research Center in Boston
New Boston research centre - +7.5 HUTCHMED & AstraZeneca file US application for ORPATHYS–TAGRISSO lung cancer combo
US filing for lung cancer combination - +7.5 FTSE 100 Today: UK Stock Market Index Rises 0.9% As Oil Prices Ease; Informa, AstraZeneca Lead Gains, Check Top Gainers And Losers
Among leading FTSE 100 gainers - +6.7 AstraZeneca opens new Boston site
New Boston site opened - +6.7 AstraZeneca stock gets a USD 2 billion Summit oncology catalyst
$2bn Summit oncology investment seen as catalyst - +6.7 AstraZeneca completes $2 billion Summit investment. AstraZeneca stock gains 1.56 percent
Completes $2bn Summit investment, shares rise - +5.8 AstraZeneca stock: Alexion to present Phase III rare-disease data at ASBMR
Alexion to present Phase III rare-disease data - +5.0 Why Zealand, AstraZeneca, and Madrigal chose Massachusetts
Massachusetts site choice covered positively - +5.0 AstraZeneca CEO Pascal Soriot on Summit ivonescimab combos
CEO discusses Summit ivonescimab combinations - +5.0 Multiply Labs Raises $75 Mln Series B Led By AstraZeneca, Teradyne
Co-leads funding round in manufacturing startup - +5.0 Why Is AstraZeneca (LSE:AZN) Stock In Focus This Week After Its Summit Therapeutics Stake?
Summit stake puts shares in focus - −4.2 AstraZeneca Takes Drug-Pricing Law Challenge To 4th Circ.
Ongoing legal challenge over drug-pricing law - +4.2 From AI to Autonomous Operations: AstraZeneca’s Supply Chain Transformation
Supply chain transformation using AI - +3.3 Pharmalittle: We're reading about U.S.-funded psychedelic trials, an AstraZeneca R&D center, and more
Newsletter mentioning R&D centre among items - +3.3 AstraZeneca Stock Technicals: Gains 1.65% on Tuesday, Momentum Weakens
Share price gain, though momentum weakening - +3.3 AstraZeneca Targets COPD Care Efficiency With Hospital Level Transition Bundle Study
COPD care study, mildly positive - +3.3 AstraZeneca’s Real World COPD Study in Russia Signals Strategic Respiratory Focus
Real-world COPD study shows respiratory focus - +3.3 Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider
Shares outperformed the market - +1.7 Innovator Interviews: AstraZeneca’s Rob Cori
Executive interview, mostly neutral - +1.3 AstraZeneca stock pre-market at EUR 141.20: plus 0.23 percent
Small pre-market share price gain - +0.8 Analia Azaro Starts New Role at AstraZeneca as Global Development Medical Director, Hematology Oncology
Routine senior hire
AstraZeneca: every day · Pharma and healthcare on 7 October 2026 · FTSE 100 overview for the day